August 26, 2019

Ascher Shmulewitz
Chief Executive Officer
Therapix Biosciences Ltd.
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel

       Re: Therapix Biosciences Ltd.
           Registration Statement on Form F-3
           Filed August 22, 2019
           File No. 333-233417

Dear Dr. Shmulewitz:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form F-3

General

1.     We note the arbitration provision in Section 22(c)(3) of your Articles
of Association filed
       as Exhibit 4.1 to your registration statement. Please revise your
prospectus to describe the
       arbitration provision and to clarify, if true, that the arbitration
provision is not mandatory
       and does not apply to claims brought under the United States federal
securities laws.
2.     We note that you have filed the Form of Amended and Restated Depositary
Agreement as
       Exhibit 4.2 to your registration statement. Please revise to file a copy
of the
       executed Depositary Agreement.

       We remind you that the company and its management are responsible for
the accuracy
 Ascher Shmulewitz
Therapix Biosciences Ltd.
August 26, 2019
Page 2

and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Sonia Bednarowski at 202-551-3666 or Dietrich King at
202-551-8071
with any questions.



FirstName LastNameAscher Shmulewitz                        Sincerely,
Comapany NameTherapix Biosciences Ltd.
                                                           Division of
Corporation Finance
August 26, 2019 Page 2                                     Office of Healthcare
& Insurance
FirstName LastName